Willdan Group's Price Target Raised by Wedbush to $120, Up 41.18%

TG Therapeutics Inc reported a robust balance sheet with significant revenue generation from BRIUMVI sales. The company faces challenges such as the need for additional capital to fund ongoing research and development. Its strengths include FDA approval and commercialization of BRIUMVI and a robust pipeline. Weaknesses include capital requirements and dependence on key products. Opportunities include market expansion and strategic collaborations to accelerate pipeline development.

TG Therapeutics Inc. (NASDAQ: TGTX) reported robust financial results for the second quarter of 2025, showcasing significant revenue generation from BRIUMVI sales. The company's total revenue for the quarter reached $141.1 million, with BRIUMVI U.S. net revenue standing at $138.8 million. This represents a 91% growth over the same period last year and a 16% increase from the first quarter of 2025 [1].

The company also announced an updated full-year 2025 BRIUMVI U.S. net revenue target of approximately $570 - $575 million, raising its previous guidance of $560 million. Additionally, the total global revenue target for 2025 was raised to approximately $585 million, up from $575 million previously [1].

Key highlights from the quarter include:

1. Commercialization Expansion: BRIUMVI's U.S. net product revenue grew significantly, with a 16% increase from the first quarter of 2025. The company has also expanded commercialization outside the U.S., with BRIUMVI approved in the European Union, United Kingdom, Switzerland, and Australia [1].

2. Pipeline Development: TG Therapeutics has made significant progress in its pipeline development. It has commenced patient enrollment into the randomized Phase 3 pivotal program to evaluate a consolidated Day 1 and Day 15 dosing regimen for IV BRIUMVI in the ongoing ENHANCE trial. Additionally, the company dosed the first patient with progressive multiple sclerosis in the Phase 1 clinical trial evaluating azer-cel for the treatment of autoimmune diseases [1].

3. Financial Performance: The company's net income for the three and six months ended June 30, 2025, was $28.2 million and $33.2 million, respectively, compared to net income (loss) of $6.9 million and $(3.8) million for the same periods in 2024. Total research and development (R&D) expense increased to approximately $31.8 million and $78.1 million for the three and six months ended June 30, 2025, respectively, primarily due to manufacturing and development costs related to the ublituximab subcutaneous development work [1].

Despite these strong financial results, TG Therapeutics faces challenges, including the need for additional capital to fund ongoing R&D efforts. The company's strengths lie in its FDA approval and commercialization of BRIUMVI, as well as a robust pipeline of innovative therapies. However, its dependence on key products and the need for capital to support further development pose potential risks.

Opportunities for TG Therapeutics include market expansion and strategic collaborations to accelerate pipeline development. The company's strong performance and promising pipeline position it well for future growth, provided it can secure the necessary capital to continue its research and development efforts.

References:

[1] https://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-reports-second-quarter-2025-financial-results